Cystic Fibrosis Therapeutics Development Network Contributes New Data Sets to C-Path's RDCA-DAP, Advancing CF Research and Treatment Strategies

TUCSON, Ariz., September 5, 2024 — Critical Path Institute (C-Path) today announced the addition of significant new data sets from the Cystic Fibrosis Therapeutics Development Network (TDN), coordinated by Seattle Children's, to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). This marks a major milestone in the collaborative efforts to enhance cystic fibrosis (CF) research and the development of effective therapies.

The CF Therapeutics Development Network, with its Coordinating Center based at Seattle Children's Research Institute, is funded by the Cystic Fibrosis Foundation and is renowned for its robust clinical trials network, evaluating the safety and effectiveness of new CF therapies. This collaboration extends the TDN's legacy of pivotal contributions to cystic fibrosis treatment advancements, complemented by Seattle Children's holistic approach to CF patient care and research.

Integrating this data with RDCA-DAP furthers the shared mission of accelerating research and therapeutic development for CF and other rare diseases. RDCA-DAP offers a cohesive and standardized infrastructure that supports, among other things, the rigorous conduct of natural history studies and provides a comprehensive, integrated database and analytics hub for clinical trial design and regulatory review.

"We deeply value the collaboration with the Cystic Fibrosis Therapeutics Development Network and Seattle Children's," said RDCA-DAP Executive Director Alexandre Bétourné, Pharm.D, Ph.D. "Enhancing our collective capabilities to tackle CF and reinforcing our platform's role in accelerating new therapies stands as a pivotal development in our partnership. Integrating these and future datasets into RDCA-DAP marks a crucial advancement in our efforts to effectively combat rare disease."

JP Clancy, M.D., Senior Vice President of Clinical Research at the Cystic Fibrosis Foundation, commented: "These efforts highlight our shared goal to foster innovative treatments for cystic fibrosis. By contributing data from CF research to this powerful platform, we will enable researchers worldwide to access and leverage data that can lead to breakthroughs in CF care."

These new data sets join numerous other contributions to RDCA-DAP, further enriching the platform's diverse and comprehensive resources necessary for groundbreaking research and therapy development.

"Innovative study designs utilizing existing data will be needed to advance therapeutic development for rare diseases, including CF, and the RDCA-DAP will be an important platform for supporting trial planning and execution," said Nicole Mayer Hamblett, Ph.D., Co-executive Director, CF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute and professor of pediatrics, University of Washington.

Organizations interested in contributing data to RDCA-DAP can visit c-path.org/rdca-dap or email rdcadap@c-path.org. The platform is OPEN and accepting applications for use; visit portal.rdca.c-path.org to learn more.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path in Europe is headquartered in Amsterdam, Netherlands with additional staff in multiple other locations. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250, and 45% funded by non-government source(s), totaling $14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

Media Contacts:

Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org

Kissy Black
C-Path
615.310.1894
kblack@c-path.org